{"id":61412,"date":"2026-03-26T15:56:19","date_gmt":"2026-03-26T07:56:19","guid":{"rendered":"https:\/\/flcube.com\/?p=61412"},"modified":"2026-03-26T15:56:20","modified_gmt":"2026-03-26T07:56:20","slug":"boehringer-ingelheim-2024-revenue-eur-27-8b-jardiance-drives-8-7-growth-rd-intensity-hits-22-9","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61412","title":{"rendered":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%"},"content":{"rendered":"\n<p><strong>Boehringer Ingelheim<\/strong> reported <strong>2024 financial results<\/strong>, with <strong>group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion)<\/strong>, driven by <strong>Human Pharma<\/strong> and <strong>Animal Health<\/strong> business momentum. <strong>R&amp;D investment surged to EUR 6.4 billion (22.9% of sales)<\/strong>, underscoring the family-owned company&#8217;s <strong>long-term innovation commitment<\/strong>. The <strong>Human Pharma division<\/strong> grew <strong>7.4% to EUR 22.7 billion<\/strong>, led by <strong>Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion<\/strong>, while <strong>2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast)<\/strong> expanded the portfolio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\">Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>2024 Net Sales<\/th><th>YoY Growth<\/th><th>Strategic Driver<\/th><\/tr><\/thead><tbody><tr><td><strong>Group Total<\/strong><\/td><td>EUR 27.8B (USD 32.2B)<\/td><td>+7.3%<\/td><td>Human Pharma + Animal Health dual engines<\/td><\/tr><tr><td><strong>Human Pharma<\/strong><\/td><td>EUR 22.7B (USD 26.26B)<\/td><td>+7.4%<\/td><td>Jardiance CRM dominance + new launches<\/td><\/tr><tr><td><strong>Animal Health<\/strong><\/td><td>EUR 5.1B (implied)<\/td><td>\u2014<\/td><td>Stable contribution<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>EUR 6.4B (USD 7.4B)<\/td><td>\u2014<\/td><td><strong>22.9% of net sales<\/strong> \u2013 industry-leading intensity<\/td><\/tr><tr><td><strong>Human Pharma R&amp;D<\/strong><\/td><td>EUR 5.8B<\/td><td>\u2014<\/td><td><strong>27.4% of segment sales<\/strong> \u2013 pipeline-heavy strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-product-performance\">Key Product Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>2024 Sales<\/th><th>YoY Growth<\/th><th>Indication<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Jardiance<\/strong> (empagliflozin)<\/td><td>EUR 8.8B (USD 10.18B)<\/td><td><strong>+8.7%<\/strong><\/td><td>CKD, T2DM, heart failure<\/td><td><strong>Blockbuster anchor<\/strong> \u2013 CRM franchise leader<\/td><\/tr><tr><td><strong>Ofev<\/strong> (nintedanib)<\/td><td>EUR 3.8B (USD 4.29B)<\/td><td>+5.4%<\/td><td>IPF, progressive fibrosing ILD<\/td><td><strong>Respiratory stable growth<\/strong> \u2013 established standard of care<\/td><\/tr><tr><td><strong>Hernexeos<\/strong> (zongertinib)<\/td><td>Launched H2 2025<\/td><td>\u2014<\/td><td>HER2-mutant NSCLC<\/td><td><strong>New oncology entrant<\/strong> \u2013 HER2 exon 20 insertion<\/td><\/tr><tr><td><strong>Jascayd<\/strong> (nerandomilast)<\/td><td>Launched H2 2025<\/td><td>\u2014<\/td><td>IPF<\/td><td><strong>Next-gen PDE4B inhibitor<\/strong> \u2013 Ofev successor potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-r-amp-d-pipeline-amp-strategic-focus\">R&amp;D Pipeline &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Pipeline Scale<\/th><th>Key Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Cardio-Renal-Metabolic (CRM)<\/strong><\/td><td>Multi-molecule<\/td><td>Jardiance combinations; SGLT2\/GLP-1 synergy<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>15+ projects<\/td><td>Zongertinib expansion; KRAS, T-cell engagers<\/td><\/tr><tr><td><strong>Respiratory &amp; Immunology<\/strong><\/td><td>10+ projects<\/td><td>PDE4B franchise; biologics for severe asthma<\/td><\/tr><tr><td><strong>Mental Health<\/strong><\/td><td>5+ projects<\/td><td>Novel mechanisms for depression, schizophrenia<\/td><\/tr><tr><td><strong>Eye Health<\/strong><\/td><td>3+ projects<\/td><td>Retinal disease biologics<\/td><\/tr><tr><td><strong>Total Pipeline<\/strong><\/td><td><strong>80+ projects, 50+ NMEs<\/strong><\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-family-owned-innovation-model\">Strategic Context: Family-Owned Innovation Model<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D Intensity<\/strong><\/td><td><strong>22.9% of sales<\/strong> vs. industry average ~15% \u2013 enables <strong>long-term bets<\/strong> without quarterly shareholder pressure<\/td><\/tr><tr><td><strong>Jardiance CRM Dominance<\/strong><\/td><td>EUR 8.8B sales approaching <strong>$10B blockbuster threshold<\/strong>; <strong>SGLT2 market leadership<\/strong> vs. Farxiga, Steglatro<\/td><\/tr><tr><td><strong>2025 Launch Execution<\/strong><\/td><td>Hernexeos + Jascayd demonstrate <strong>oncology and respiratory renewal<\/strong> \u2013 reduces Ofev patent cliff risk<\/td><\/tr><tr><td><strong>Pipeline Depth<\/strong><\/td><td><strong>50+ NMEs<\/strong> provides <strong>10-year revenue visibility<\/strong>; rare for mid-cap pharma<\/td><\/tr><tr><td><strong>Animal Health Stability<\/strong><\/td><td>EUR 5B+ segment provides <strong>cash flow diversification<\/strong> and <strong>crisis resilience<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025 Catalysts:<\/strong> Jardiance <strong>heart failure with preserved ejection fraction (HFpEF) label expansion<\/strong>; zongertinib <strong>Phase II combination data<\/strong>; nerandomilast <strong>real-world IPF efficacy<\/strong><\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Private ownership enables <strong>$6.4B R&amp;D bet<\/strong> on <strong>CRM + oncology<\/strong> while peers face margin pressure; <strong>Jardiance + Ofev cash cows<\/strong> fund innovation<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding 2025 launch performance, pipeline progression, and Jardiance market expansion. Actual results may differ due to competitive dynamics with SGLT2\/GLP-1 combinations, regulatory review timelines for pipeline assets, and Animal Health market volatility.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/Boehringer-Ingelheim-Annual-Report-Highlights-2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Boehringer-Ingelheim-Annual-Report-Highlights-2025.\"><\/object><a id=\"wp-block-file--media-27a94ecd-5d46-40f4-9ab4-24c7dae883ad\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/Boehringer-Ingelheim-Annual-Report-Highlights-2025.pdf\">Boehringer-Ingelheim-Annual-Report-Highlights-2025<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/Boehringer-Ingelheim-Annual-Report-Highlights-2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-27a94ecd-5d46-40f4-9ab4-24c7dae883ad\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61415,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-61412","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&amp;D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company&#039;s long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61412\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&amp;D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company&#039;s long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61412\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-26T07:56:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-26T07:56:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%\",\"datePublished\":\"2026-03-26T07:56:19+00:00\",\"dateModified\":\"2026-03-26T07:56:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2606.webp\",\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61412#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61412\",\"name\":\"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2606.webp\",\"datePublished\":\"2026-03-26T07:56:19+00:00\",\"dateModified\":\"2026-03-26T07:56:20+00:00\",\"description\":\"Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company's long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61412\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2606.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61412#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9% - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company's long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61412","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%","og_description":"Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company's long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.","og_url":"https:\/\/flcube.com\/?p=61412","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-26T07:56:19+00:00","article_modified_time":"2026-03-26T07:56:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61412#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61412"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%","datePublished":"2026-03-26T07:56:19+00:00","dateModified":"2026-03-26T07:56:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61412"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61412#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp","articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61412#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61412","url":"https:\/\/flcube.com\/?p=61412","name":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61412#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61412#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp","datePublished":"2026-03-26T07:56:19+00:00","dateModified":"2026-03-26T07:56:20+00:00","description":"Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company's long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61412#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61412"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61412#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61412#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim 2024 Revenue EUR 27.8B \u2013 Jardiance Drives 8.7% Growth, R&amp;D Intensity Hits 22.9%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61412"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61412\/revisions"}],"predecessor-version":[{"id":61416,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61412\/revisions\/61416"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61415"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}